We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Erin
Greaves
Erin.Greaves@Warwick.ac.uk
Dr
Erin
Greaves
Erin.Greaves@Warwick.ac.uk
Noninflammatory disorders of female genital tract
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Endometriosis affects approximately 176 million women worldwide and is associated with debilitating pelvic pain and/or infertility. Endometriosis is defined by the presence of tissue similar to womb lining (endometrium) outside the womb (lesions), most commonly on the wall of the pelvic cavity. Endometriosis is currently treated surgically or with drugs that suppress sex hormones. However, symptoms often recur after surgery and available medical treatments have undesirable side-effects and are contraceptive. New treatments for endometriosis are desperately needed.
Endometriosis is primarily an inflammatory disorder exhibiting a large degree of symptom and disease presentation.
The aims of this study are
1. To unravel the degree of disease diversity by evaluating the gene expression profile of single cells in different types of endometriosis lesion
2. To identify cells that exhibit disease-modified characteristics
3. To identify new targets representing potential biomarkers or therapeutic intervention
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
1. Pregnant or lactating women 2. Known reproductive tract malignancy 3. Known to be HIV positive 4. Known active hepatitis B and/ or hepatitis C infection
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Warwick and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41788
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
